Remab Therapeutics

Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.We have developed RA-01, a novel drug product and a first line therapy for preventing infectious diseases at ICUs. Simultaneously we have under research several new indications that will be added to our pipeline soon.